Global Fibrotic Diseases Treatment Market - Industry Trends and Forecast to 2030

Global Fibrotic Diseases Treatment Market - Industry Trends and Forecast to 2030

Global Fibrotic Diseases Treatment Market, By Treatment (Medication, Organ Transplantation, Oxygen Therapy, Others), Application (Idiopathic Pulmonary Fibrosis, Hepatic Cirrhosis, Renal Fibrosis, Cutaneous Fibrosis, Others), End User (Hospitals, Specialty Clinics, Academic and Research Institutes, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Country (U.S., Canada, Mexico, Dominican Republic, Jamaica, Panama Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Taiwan Rest of Asia-Pacific, Brazil, Ecuador, Chile, Colombia, Venezuela, Argentina, Peru, Curaçao, Paraguay, Uruguay, Trinidad And Tobago, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Kuwait, Bahrain Israel, Rest of the Middle East and Africa) Industry Trends and Forecast to 2030

Market Definition

The term fibrosis describes the development of fibrous connective tissue as a reparative response to injury or damage. Fibrosis may refer to the connective tissue deposition that occurs as part of normal healing or to the excess tissue deposition that occurs as a pathological process. Diseases characterized by uncontrolled, progressive fibrosis include Idiopathic Pulmonary Fibrosis (IPF), Non-Alcoholic Steatohepatitis (NASH), and Systemic Sclerosis (SSc).

Fibrosis is a group of serious organ/tissue diseases that affect the tissue system. Fibrosis scars and thickens the tissue. It impacts the connecting tissue, for instance, in the lung and the alveoli (air sacs inside the lungs). The lung damage gradually gets worse over time. Hard, stiff lung tissues don’t expand as well as they should, making it harder to breathe. Pulmonary fibrosis may cause shortness of breath when you do routine tasks that never seemed tiring before.

Market Segmentation

The global fibrotic diseases treatment market is categorized into four notable segments such as treatment, application, end user, and distribution channel.
• On the basis of treatment, the fibrotic diseases treatment market is segmented into medication, organ transplantation, oxygen therapy, and others
• On the basis of application, the fibrotic diseases treatment market is segmented into idiopathic pulmonary fibrosis, hepatic cirrhosis, renal fibrosis, cutaneous fibrosis, and others
• On the basis of end user, the fibrotic diseases treatment market is segmented into hospitals, specialty clinics, academic and research institutes, and others
• On the basis of distribution channel, the fibrotic diseases treatment market is segmented into hospital pharmacy, retail pharmacy, and others

Market Players

Some of the key market players in the global fibrotic diseases treatment market are listed below:
• Genentech, Inc.
• Boehringer Ingelheim International GmbH
• AbbVie Inc.
• Redx Pharma Plc
• Bristol-Myers Squibb Company
• BellBrook Labs
• Enveda Biosciences
• BioMX
• Gilead Sciences, Inc.
• KITHER BIOTECH S.R.L.
• Verona Pharma plc
• Alpine Immune Sciences
• Intercept Pharmaceuticals, Inc.
• Pharmaxis Ltd.
• Teva Pharmaceutical Industries Ltd.
• Sandoz International GmbH
• Accord Healthcare
• Camber Pharmaceuticals, Inc

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.